Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG2 | P78540 | 5/20 | 1.00 |
| ▸ | ARG1 | P05089 | 4/20 | 1.00 |
| ▸ | GGT1 | P19440 | 4/20 | 0.55 |
| ▸ | NOS2 | P35228 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | BHMT | Q93088 | 4/20 | 0.39 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18543021 | 1.00 | ARG2 (1.00) | ARG2ARG1GGT1NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL23013877 | 0.98 | ARG2 (0.96) | ARG2ARG1GGT1NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL23013879 | 0.98 | ARG2 (0.96) | ARG2ARG1GGT1NOS2NOS1 | |
| SCHEMBL17361239 | 0.83 | ARG1 (0.69) | ARG2ARG1NOS2NOS1NOS3 | |
| SCHEMBL17361240 | 0.83 | ARG1 (0.69) | ARG2ARG1NOS2NOS1NOS3 | |
| SCHEMBL36934 | 0.78 | ARG1 (0.61) | ARG2ARG1GGT1NOS2NOS1 | |
| SCHEMBL36935 | 0.78 | ARG1 (0.61) | ARG2ARG1GGT1NOS2NOS1 | |
| SCHEMBL29378137 | 0.78 | ARG1 (0.61) | ARG2ARG1GGT1NOS2NOS1 | |
| SCHEMBL29393779 | 0.78 | ARG1 (0.61) | ARG2ARG1GGT1NOS2NOS1 | |
| SCHEMBL36933 | 0.78 | ARG1 (0.61) | ARG2ARG1GGT1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | claimed |
| US-11576933-B2 | Compositions and methods for an improved antitumor immune response | Effector Therapeutics Inc. (US) | 2023-02-14 | — | — | US | claimed |
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | claimed |
| US-20210238250-A9 | BRAF-SPECIFIC TCRS AND USES THEREOF | FRED HUTCHINSON CANCER CENTER | 2021-08-05 | — | — | US | claimed |
| US-20200405762-A1 | CYCLIN A1 SPECIFIC T CELL RECEPTORS AND USES THEREOF | FRED HUTCHINSON CANCER CENTER | 2020-12-31 | — | — | US | claimed |
| EP-3752525-A1 | CYCLIN A1 SPECIFIC T CELL RECEPTORS AND USES THEREOF | Fred Hutchinson Cancer Research Center (US) | 2020-12-23 | — | — | EP | claimed |
| CN-106029896-B | Modulation of ornithine metabolism to manipulate high mannose glycoform content of recombinant proteins | 美国安进公司 | 2020-10-27 | — | — | CN | claimed |
| EP-3697435-A1 | COMPOSITIONS AND METHODS OF IMMUNOTHERAPY TARGETING TIGIT AND/OR CD112R OR COMPRISING CD226 OVEREXPRESSION | Fred Hutchinson Cancer Research Center (US) | 2020-08-26 | — | — | EP | claimed |
| US-20200223899-A1 | BRAF-SPECIFIC TCRS AND USES THEREOF | HUTCHINSON FRED CANCER RES (US) | 2020-07-16 | — | — | US | claimed |
| EP-2355657-A1 | COMPOSITIONS AND METHODS OF TREATING ENDOTHELIAL DISORDERS | Arginetix, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| WO-2010062366-A1 | COMPOSITIONS AND METHODS OF TREATING ENDOTHELIAL DISORDERS | ARGINETIX, INC. (US) | 2010-06-03 | — | — | WO | claimed |
| US-20100056480-A1 | USE OF ARGINASE INHIBITORS IN THE TREATMENT OF ASTHMA AND ALLERGIC RHINITIS | Rijks Univesiteit Groningen | 2010-03-04 | — | — | US | claimed |
| EP-2083812-A1 | USE OF ARGINASE INHIBITORS IN THE TREATMENT OF ASTHMA AND ALLERGIC RHINITIS | Rijksuniversiteit Groningen (NL) | 2009-08-05 | — | — | EP | claimed |
| WO-2008061612-A1 | USE OF ARGINASE INHIBITORS IN THE TREATMENT OF ASTHMA AND ALLERGIC RHINITIS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2008-05-29 | — | — | WO | claimed |
| EP-1863431-A1 | HAIR AND/OR EYELASH CARE COMPOSITION CONTAINING AMINEXIL IN COMBINATION WITH AN AGENT FOR PROMOTING THE NO PRODUCTION AND USES THEREOF | L'Oréal (FR) | 2007-12-12 | — | — | EP | claimed |
| WO-2006097359-A1 | HAIR AND/OR EYELASH CARE COMPOSITION CONTAINING AMINEXIL IN COMBINATION WITH AN AGENT FOR PROMOTING THE NO PRODUCTION AND USES THEREOF | L'ORÉAL (FR) | 2006-09-21 | — | — | WO | claimed |
| US-20040057926-A1 | Modulation of the immune response through the manipulation of arginine levels | LSU MEDICAL CENTER | 2004-03-25 | — | — | US | claimed |
| WO-2003078578-A2 | MODULATION OF THE IMMUNE RESPONSE THROUGH THE MANIPULATION OF ARGININE LEVELS | LSU MEDICAL CENTER (US) | 2003-09-25 | — | — | WO | claimed |
| US-6444237-B1 | ADMINISTERING BY MOUTH A MIXTURE OF AMINO ACID AND PLANT EXTRACTS | IPR INVESTMENTS, LLC | 2002-09-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576933-B2 | Compositions and methods for an improved antitumor immune response | EIF4A2, EIF4A1, EIF4EBP1 | ARG2 714/4885ARG1 488/4885GGT1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.